JP2024511995A - がん治療における第一選択療法としてのｓＥｐｈＢ４－ＨＳＡ融合タンパク質の使用 - Google Patents

がん治療における第一選択療法としてのｓＥｐｈＢ４－ＨＳＡ融合タンパク質の使用 Download PDF

Info

Publication number
JP2024511995A
JP2024511995A JP2023557284A JP2023557284A JP2024511995A JP 2024511995 A JP2024511995 A JP 2024511995A JP 2023557284 A JP2023557284 A JP 2023557284A JP 2023557284 A JP2023557284 A JP 2023557284A JP 2024511995 A JP2024511995 A JP 2024511995A
Authority
JP
Japan
Prior art keywords
cancer
treatment
sephb4
ephb4
kras
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557284A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511995A5 (enExample
Inventor
クラスノペロフ，ヴァレリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2024511995A publication Critical patent/JP2024511995A/ja
Publication of JP2024511995A5 publication Critical patent/JP2024511995A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023557284A 2021-03-18 2022-03-18 がん治療における第一選択療法としてのｓＥｐｈＢ４－ＨＳＡ融合タンパク質の使用 Pending JP2024511995A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162691P 2021-03-18 2021-03-18
US63/162,691 2021-03-18
PCT/US2022/020878 WO2022198001A1 (en) 2021-03-18 2022-03-18 Use of sephb4-hsa fusion protein as a first-line therapy in cancer treatment

Publications (2)

Publication Number Publication Date
JP2024511995A true JP2024511995A (ja) 2024-03-18
JP2024511995A5 JP2024511995A5 (enExample) 2025-06-23

Family

ID=83320877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557284A Pending JP2024511995A (ja) 2021-03-18 2022-03-18 がん治療における第一選択療法としてのｓＥｐｈＢ４－ＨＳＡ融合タンパク質の使用

Country Status (8)

Country Link
US (1) US20240156908A1 (enExample)
EP (1) EP4308149A4 (enExample)
JP (1) JP2024511995A (enExample)
KR (1) KR20230173108A (enExample)
CN (1) CN117120074A (enExample)
AU (1) AU2022239581A1 (enExample)
CA (1) CA3211742A1 (enExample)
WO (1) WO2022198001A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020190977A1 (en) * 2019-03-17 2020-09-24 Vasgene Therapeutics Inc Treatment of cancers using sephb4-hsa fusion proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274305B1 (en) * 1996-12-19 2001-08-14 Tufts University Inhibiting proliferation of cancer cells
WO2006034455A2 (en) * 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
WO2012068477A1 (en) * 2010-11-19 2012-05-24 Vasgene Therapeutics, Inc. Methods and compositions for inhibiting angiogenesis and tumor growth
JP6877419B2 (ja) * 2015-10-27 2021-05-26 ザ ユニバーシティー オブ クイーンズランド 治療の方法およびそのために有用な剤
CA3139416A1 (en) * 2019-02-13 2020-08-20 Vasgene Therapeutics Inc Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020190977A1 (en) * 2019-03-17 2020-09-24 Vasgene Therapeutics Inc Treatment of cancers using sephb4-hsa fusion proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLINICAL CANCER RESEARCH, vol. 24, no. 18, JPN6026019550, 2018, pages 4539 - 4550, ISSN: 0005862373 *
MOLECULAR CANCER THERAPEUTICS, vol. 9, no. 8, JPN6026019548, 2010, pages 2377 - 2388, ISSN: 0005862375 *
PLOS ONE, vol. Vol. 8，Issue 7, JPN6026019549, 2013, pages 67668, ISSN: 0005862374 *

Also Published As

Publication number Publication date
US20240156908A1 (en) 2024-05-16
AU2022239581A1 (en) 2023-10-26
WO2022198001A1 (en) 2022-09-22
KR20230173108A (ko) 2023-12-26
EP4308149A4 (en) 2025-02-26
CN117120074A (zh) 2023-11-24
EP4308149A1 (en) 2024-01-24
CA3211742A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
TWI780994B (zh) 用於治療非小細胞肺癌之抗b7-h1及抗ctla-4抗體
Prenen et al. Role of targeted agents in metastatic colorectal cancer
DK2101807T3 (en) VEGF-SPECIFIC ANTAGONISTS FOR ADMINISTRATIVE AND NEOADVERTIVE TREATMENT AND TREATMENT OF TEMPERATURES IN EARLY STAGE
KR101807319B1 (ko) 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
JP7809324B2 (ja) ｓＥｐｈＢ４－ＨＳＡ融合タンパク質を用いたがんの治療
JP2014508782A (ja) ホルモン不応性乳癌の治療におけるｅｇｆｒファミリー受容体の阻害剤の使用
CA3173797A1 (en) Method for allowing immune cells infiltration in tumors
JP2026514110A (ja) がんの処置および予防のための組合せ
US20240156908A1 (en) USE OF sEphB4-HSA FUSION PROTEIN AS A FIRST-LINE THERAPY IN CANCER TREATMENT
KR20240053651A (ko) 에프린b2 발현을 이용한 암의 진단 방법
KR20250131777A (ko) 암의 치료 및 예방을 위한 조합물
AU2014201795B2 (en) VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
Hewish et al. Insulin-Like Growth Factor Receptor Inhibitors: Categorical Lack of Efficacy or Lack of Personalised Medicine?
AU2016213830A1 (en) VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
HK1133210B (en) Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260806